Remedium Lifecare Posts Strong Q2 And H1 Growth Momentum

18 Nov 2025 CW Team

For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26.

For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025.

Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth.

Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities.

The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Remedium Lifecare Limited has announced its consolidated financial results for the quarter and half-year ended 30 September 2025, reporting strong operational momentum and continued progress in business expansion. For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26. For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025. Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth. Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities. The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Infrastructure Transport

05 Feb 2026

MMRDA Installs 325-Tonne Steel Spans on Mumbai Metro Line 4

The Mumbai Metropolitan Region Development Authority (MMRDA) has achieved a key construction milestone on Metro Line 4 with the successful installation of three large steel spans at Bhandup West during overnight operations.The spans, together weighing 325 metric tonnes, were launched using eight heavy-duty cranes and 12 multi-axle vehicles. The operation required precise engineering and meticulous planning to minimise disruption in the densely populated suburban area.Due to effective inter-agency coordination, the work—originally scheduled across four nights—was completed within just two n..

Infrastructure Transport

05 Feb 2026

CMRL Targets March 2027 Opening for Vadapalani–Panagal Park

Chennai Metro Rail Limited (CMRL) is progressing as scheduled to open the Vadapalani–Panagal Park section of Phase II’s Corridor 4 by March 2027. The 3.5 km underground stretch is part of the 26.1 km Corridor 4 connecting Lighthouse with Poonamallee Bypass.Construction activities are advancing steadily, with tunnelling works between Vadapalani and Panagal Park already completed. Track-laying operations are expected to commence shortly. At Panagal Park station, structural works have reached the concourse and platform levels, while excavation continues at the lowest level.CMRL is also consid..

Infrastructure Transport

05 Feb 2026

Maha-Metro Invites Pune Metro Civil Maintenance Bids

Maharashtra Metro Rail Corporation Limited (Maha-Metro) has invited bids for the annual civil maintenance contract of the Pune Metro Rail Project. The tender, bearing ID and number P1-O&M-20/2025, is scheduled to close on 23 February 2026, with a pre-bid meeting slated for 10 February 2026. The earnest money deposit (EMD) for the contract is Rs 3,50,500, and the duration of the contract is one year.The scope of work includes annual civil maintenance of 28 elevated and underground stations, 28.079 km of elevated viaduct including steel bridges, 12.15 km of tunnels, and two depots under the ..